 |
| |
 |
| |
 |
| |
 |
| |
 |
_____________________________________________________________________________________________________________________
© 2005-9 All Rights Reserved. NOD Pharmaceuticals, Inc.
the closing of series B financing of US$5.5 million. BioVeda China is the leading investor in this
series of financing.
"The proceeds from series B funding will allow the Company to complete clinical development of
its leading product candidate, Nodlin, in China", William Lee, CEO of NOD Pharmaceuticals,
explains.
Oral insulin and other products are developed with nano-particle oral delivery or NOD technology
and are being developed first in China to take advantages of the lower cost and short development
cycle in China.
NOD technology uses nano-partilces as carrier to efficiently deliver bio-active macromolecular drugs
such as insulin or interferon via oral route. NOD Pharmaceuticals, Inc. is a biopharmaceutical
company focusing on innovative drug delivery.
Other investors participated in this round of financing include China Renaissance Capital
Investment, Besto Holdings, and BioVeda.
SOURCE NOD Pharmaceuticals, Inc.
William Lee, Ph.D, CEO of NOD Pharmaceuticals, Inc., 86-21-5132-0478
www.nodpharm.com
info@nodpharm.com
series of financing.
"The proceeds from series B funding will allow the Company to complete clinical development of
its leading product candidate, Nodlin, in China", William Lee, CEO of NOD Pharmaceuticals,
explains.
Oral insulin and other products are developed with nano-particle oral delivery or NOD technology
and are being developed first in China to take advantages of the lower cost and short development
cycle in China.
NOD technology uses nano-partilces as carrier to efficiently deliver bio-active macromolecular drugs
such as insulin or interferon via oral route. NOD Pharmaceuticals, Inc. is a biopharmaceutical
company focusing on innovative drug delivery.
Other investors participated in this round of financing include China Renaissance Capital
Investment, Besto Holdings, and BioVeda.
SOURCE NOD Pharmaceuticals, Inc.
William Lee, Ph.D, CEO of NOD Pharmaceuticals, Inc., 86-21-5132-0478
www.nodpharm.com
info@nodpharm.com
Press Release
 |  |  |
| NOD Pharmaceuticals, Inc. closes series B financing |
NOD
Pharmaceuticals, Inc.
| Innovation Delivered |
| | |